Results 181 to 190 of about 1,590,116 (307)

A cluster randomized trial of a health coach-led patient activation program in type 2 diabetes in Singapore - a study protocol. [PDF]

BMC Prim Care
Lee JHB, Yeo LS, Soon WSW, Ding SY, Ge L, Pereira MJ, Foo SCL, Chern CWF, Wong SKW.   +8 more
europepmc   +1 more source

Influence of Participation in a Medical-Themed Science Café on Patient Activation. [PDF]

Patient Prefer Adherence, 2023
Okazawa Y, Kizaki H, Suzuki N, Osaka W, Hori S.   +4 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Validation of the Patient Activation Measure in kidney stone disease patients. [PDF]

Can Urol Assoc J
Murad L, Samra SA, Schwartz R, Assad A, Penniston K, Bensaadi K, Meskawi M, Bhojani N.   +7 more
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Profiles of resilience and patient activation among patients with colorectal cancer and an enterostomy: A latent profile analysis. [PDF]

Asia Pac J Oncol Nurs
Su J, Liu X, Deng X, Zhang H, Li X, Yuan L, Zhou A.   +6 more
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Digital Health Outreach to Increase Patient Activation and Reduce 30-Day Readmissions After Heart Failure Hospitalizations. [PDF]

JACC Case Rep
Kubo SH, Quiroz S, Caplan J, Onstott C, Duvall L.   +4 more
europepmc   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

The mental-health patient-activation measure: assessing validity, reliability, and responsiveness in outpatient settings. [PDF]

BMC Psychiatry
Skliarova T, Lara-Cabrera ML, Brobakken MF, Heggelund J, Vedul-Kjelsås E, Güzey IC, Hafstad H, Reitan SK, Nygård M.   +8 more
europepmc   +1 more source